drugset
drugset / Trial / NCT01037309

Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD)

NCT01037309 ↗

Phase 1/2 Completed 18 enrolled BioMarin Pharmaceutical
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to see whether PRO044 is safe and effective to use as medication for DMD patients with a mutation around location 44 in the DNA for the dystrophin protein.

Timeline

Start
2009-12
Primary completion
2013-05
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject PRO044 Unknown 0.5 mg/kg Subcutaneous
Subject PRO044 Unknown 1.5 mg/kg Subcutaneous
Subject PRO044 Unknown 5 mg/kg Subcutaneous
Subject PRO044 Unknown 8 mg/kg Subcutaneous
Subject PRO044 Unknown 10 mg/kg Subcutaneous
Subject PRO044 Unknown 12 mg/kg Subcutaneous

Indications

Duchenne muscular dystrophy